We read the article by Ramalingam et al¹ that described the ECOG-ACRIN 5508 study. This randomized, controlled, phase III trial found that the combination of bevacizumab and pemetrexed, compared with bevacizumab or pemetrexed as maintenance therapy, for advanced nonsquamous non–small-cell lung cancer (NSCLC) significantly improved progression-free survival (PFS) but lacked overall survival (OS) benefit and had higher toxicity. Therefore, single-agent bevacizumab or pemetrexed was recommended as maintenance therapy for advanced nonsquamous NSCLC. However, some aspects of the study warrant closer attention.

中文翻译：

---

晚期非鳞状非小细胞肺癌的维持疗法：比答案更多的问题。

我们阅读了Ramalingam等人¹的文章，其中描述了ECOG-ACRIN 5508研究。这项随机，对照的III期临床试验发现，贝伐单抗和培美曲塞的联合治疗与贝伐单抗或培美曲塞的联合治疗相比，晚期非鳞状非小细胞肺癌（NSCLC）可以显着改善无进展生存期（PFS），但缺乏总生存期（OS）受益，并且毒性更高。因此，推荐单药贝伐单抗或培美曲塞作为晚期非鳞状非小细胞肺癌的维持治疗。但是，该研究的某些方面值得密切关注。